Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
- Generic Name
- Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
- Brand Names
- Adacel, Boostrix, Daptacel, Diphtheria and Tetanus Toxoids Adsorbed, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, Td Adsorbed, Tdvax, Tenivac, Vaxelis
- Drug Type
- Biotech
- CAS Number
- 308079-75-6
- Unique Ingredient Identifier
- IRH51QN26H
- Associated Conditions
- Diphtheria, Tetanus
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal Immunization
- Interventions
- Biological: PCV21 vaccineBiological: Prevnar 20 vaccineBiological: M-M-R II vaccine
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2320
- Registration Number
- NCT06824194
- Locations
- 🇭🇳
Investigational Site Number : 3400003, Tegucigalpa, Honduras
🇵🇷Investigational Site Number : 6300002, Bayamon, Puerto Rico
🇭🇳Investigational Site Number : 3400001, San Pedro Sula, Honduras
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal Immunization
- Interventions
- Biological: PCV21 vaccineBiological: Prevnar 20 vaccineBiological: M-M-R II vaccine
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 580
- Registration Number
- NCT06824181
- Locations
- 🇺🇸
The Medici Medical Research- Site Number : 8400008, Hollywood, Florida, United States
🇺🇸Atlantis Clinical Research, LLC- Site Number : 8400009, Miami, Florida, United States
🇺🇸Helios- Site Number : 8400016, Burleson, Texas, United States
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- Conditions
- Pneumococcal Immunization
- Interventions
- Biological: PCV21 vaccineBiological: Prevnar 20 vaccineBiological: M-M-R II vaccineBiological: Hexaxim Vaccine
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1630
- Registration Number
- NCT06736041
- Locations
- 🇺🇸
Eclipse Clinical Research- Site Number : 8400029, Tucson, Arizona, United States
🇺🇸Northwest Arkansas Pediatrics- Site Number : 8400030, Fayetteville, Arkansas, United States
🇺🇸Century Research Institute- Site Number : 8400065, Huntington Park, California, United States
PFAS Exposure and Immune Response to Vaccination in Adults
- Conditions
- Innate Inflammatory ResponseVaccinationDiphtheriaTetanusEnvironmental ExposureVaccineAntibodiesAdultImmunityPollution; Exposure
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 20
- Registration Number
- NCT06588530
- Locations
- 🇺🇸
EOHSI Paulsboro Office, Paulsboro, New Jersey, United States
Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant Women
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Farzanah Laher
- Target Recruit Count
- 511
- Registration Number
- NCT05264662
- Locations
- 🇿🇦
Chris Hani Baragwanath Academic Hospital, Johannesburg, GP, South Africa
Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)
- Conditions
- Haemophilus Influenzae Type B Infection
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 333
- Registration Number
- NCT04978818
- Locations
- 🇺🇸
Shiprock Center for Indigenous Health, Shiprock, New Mexico, United States
🇺🇸Gallup Center for Indigenous Health, Gallup, New Mexico, United States
🇺🇸Fort Defiance Center for Indigenous Health, Fort Defiance, Arizona, United States
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
- Conditions
- Infections, Meningococcal
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1196
- Registration Number
- NCT03621670
- Locations
- 🇬🇧
GSK Investigational Site, Edinburg, United Kingdom
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 84
- Registration Number
- NCT02543918
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants
- Conditions
- Responses to Infant Immunisations
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Public Health England
- Target Recruit Count
- 366
- Registration Number
- NCT02145624
- Locations
- 🇬🇧
Hertfordshire, Hertfordshire, United Kingdom
🇬🇧Gloucestershire, Gloucestershire, United Kingdom
🇬🇧St George's Vaccine Institute, London, United Kingdom
Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2007-08-09
- Lead Sponsor
- Norwegian Institute of Public Health
- Target Recruit Count
- 83
- Registration Number
- NCT00514059
- Locations
- 🇳🇴
Norwegian Institute of Public Health, Oslo, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.